ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
NCT ID: NCT00934050
Last Updated: 2019-10-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
103 participants
INTERVENTIONAL
2009-06-30
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ELND005 in Patients With Mild to Moderate Alzheimer's Disease
NCT00568776
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
NCT01735630
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
NCT01766336
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
NCT05231785
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
NCT00930059
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ELND005
ELND005 (scyllo-inositol)
Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks
After 15Dec2009: ELND005 250 mg PO BID for 48 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ELND005 (scyllo-inositol)
Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks
After 15Dec2009: ELND005 250 mg PO BID for 48 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
OPKO Health, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner Alzheimer's Institute
Phoenix, Arizona, United States
Sun Health Research Institute
Sun City, Arizona, United States
University of Arizona, Health Sciences Center, Dept. of Neurology
Tucson, Arizona, United States
Margolin Brain Institute
Fresno, California, United States
Collaborative NeuroScience Network, Inc.
Garden Grove, California, United States
Yale University School of Medicine, Alzheimer's Disease Research Unit
New Haven, Connecticut, United States
Brain Matters Research
Delray Beach, Florida, United States
Sunrise Clinical Research, Inc
Hollywood, Florida, United States
Roskamp Institute
Sarasota, Florida, United States
Premiere Research Institute
West Palm Beach, Florida, United States
Emory University, Dept. of Neurology
Atlanta, Georgia, United States
Dekalb Neurology Associates, LLC
Decatur, Georgia, United States
Department of Neurology - Indiana University Medical Center
Indianapolis, Indiana, United States
University of Kansas Medical Center, Department of Neurology
Kansas City, Kansas, United States
Innovative Clinical Concepts
Paducah, Kentucky, United States
Memory Enhancement Center of America, Inc.
Eatontown, New Jersey, United States
Global Medical Institutes
Princeton, New Jersey, United States
Albuquerque Neuroscience, Inc.
Albuquerque, New Mexico, United States
Neurological Associates of Albany, PC
Albany, New York, United States
Columbia University Sergievsky Center
New York, New York, United States
AD-CARE, Monroe Community Hospital
Rochester, New York, United States
Raleigh Neurology Associates
Raleigh, North Carolina, United States
Neurology & Neuroscience Center of Ohio
Toledo, Ohio, United States
Medford Neurological and Spine Clinic
Medford, Oregon, United States
Summit Research Newtwork, Inc.
Portland, Oregon, United States
The Clinical Trial Center, LLC
Jenkintown, Pennsylvania, United States
University of Pittsburgh Alzheimer Disease Research Clinic
Pittsburgh, Pennsylvania, United States
Butler Hospital, Memory and Aging Center
Providence, Rhode Island, United States
Alliance for Neuro Research, LLC dba Absher Neurology, PA
Greenville, South Carolina, United States
Clinical Neuroscience Research Associates, Inc-The Memory Clinic
Bennington, Vermont, United States
Glenrose Rehabilitation Hospital
Edmonton, Alberta, Canada
University of British Columbia Hospital, Division of Neurology
Vancouver, British Columbia, Canada
Parkwood Hospital
London, Ontario, Canada
Sisters of Charity of Ottawa Health Service
Ottawa, Ontario, Canada
Kawartha Regional Memory Clinic
Peterborough, Ontario, Canada
Whitby Mental Health Memory Clinic
Toronto, Ontario, Canada
Gerontion Research, Inc.
Toronto, Ontario, Canada
Recherche Clinique de Neurologie (Hospital Maisonneuve Rosemont)
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ELND005-AD251
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.